Sun, Sep 21, 2014, 9:07 AM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • biobottom biobottom Sep 27, 2013 6:52 PM Flag

    Kadcyla beats Herceptin: Take note

    By Simeon Bennett - Sep 27, 2013 12:43 PM PT
    “Few drugs have been able to achieve both improved progression-free survival and a better toxicity profile,” Hans Wildiers, who led the study at the University Hospitals Leuven in Belgium, said in a statement. The results show Kadcyla “has the potential to be a new treatment paradigm for this group of patients who currently have few options.”
    Kadcyla, also known as T-DM1, is a so-called antibody-drug conjugate that combines Herceptin with a cell-killing drug called DM1 using technology licensed from Waltham, Massachusetts-based ImmunoGen Inc. (IMGN) that shepherds the drug directly to the cancer cell, reducing collateral damage to healthy cells.

    Sentiment: Buy

11.35+0.01(+0.09%)Sep 19 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.